Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Opiant Pharmaceuticals reports Q2 EPS (45c), consensus (24c) » 16:51
08/06/20
08/06
16:51
08/06/20
16:51
OPNT

Opiant Pharmaceuticals

$9.14 /

-0.06 (-0.65%)

Reports Q2 revenue…

Reports Q2 revenue $6.26M, consensus $6.08M. Commenting on the quarter, Roger Crystal, president and CEO of Opiant, said: "During the past quarter, we made important progress in developing and advancing our lead product candidate, OPNT003 nasal nalmefene, a potential new treatment for opioid overdose, towards NDA filing in 2021, and subsequent potential commercial launch. CDC provisional data for 2019 shows that the opioid epidemic in America is shifting further toward more potent fentanyl and other synthetic opioids, underlying the urgent medical need for a more powerful opioid rescue medication."

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$9.14 /

-0.06 (-0.65%)

OPNT Opiant Pharmaceuticals
$9.14 /

-0.06 (-0.65%)

Over a month ago
Hot Stocks
Opiant Pharmaceuticals 'disappointed' with court decision in patent case » 15:14
06/07/20
06/07
15:14
06/07/20
15:14
TEVA

Teva

$12.84 /

+0.09 (+0.71%)

, OPNT

Opiant Pharmaceuticals

$11.70 /

+0.09 (+0.78%)

The U.S. District Court…

The U.S. District Court for the District of New Jersey has entered a decision in the patent litigation regarding NARCAN Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuticals (TEVA). Opiant's (OPNT) commercial partner Emergent BioSolutions, intends to appeal the decision to the Court of Appeals for the Federal Circuit. "While we are disappointed by the decision today, we are mindful of the important role NARCAN Nasal Spray plays across the United States in helping our communities save lives from opioid overdose," said Roger Crystal, President and Chief Executive Officer of Opiant. "With our pipeline and strong financial position, we remain committed to develop best-in-class medicines for addiction and overdose."

ShowHide Related Items >><<
TEVA Teva
$12.84 /

+0.09 (+0.71%)

OPNT Opiant Pharmaceuticals
$11.70 /

+0.09 (+0.78%)

TEVA Teva
$12.84 /

+0.09 (+0.71%)

06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 Truist
Teva upgraded to Buy from Hold at SunTrust
06/01/20 Truist
Teva upgraded to Buy from Hold at SunTrust
05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
OPNT Opiant Pharmaceuticals
$11.70 /

+0.09 (+0.78%)

TEVA Teva
$12.84 /

+0.09 (+0.71%)

OPNT Opiant Pharmaceuticals
$11.70 /

+0.09 (+0.78%)

TEVA Teva
$12.84 /

+0.09 (+0.71%)

TEVA Teva
$12.84 /

+0.09 (+0.71%)

TEVA Teva
$12.84 /

+0.09 (+0.71%)

Over a quarter ago
Earnings
Opiant says well positioned with significant cash, no debt » 16:17
05/12/20
05/12
16:17
05/12/20
16:17
OPNT

Opiant Pharmaceuticals

$11.94 /

-0.46 (-3.71%)

David O'Toole, CFO…

David O'Toole, CFO of Opiant, said: "We are well-positioned financially with significant cash, no debt and no need to access government programs in the United States or United Kingdom for COVID-19-related financial assistance or relief. Our pipeline investments and overall financial position continue to benefit from a resilient stream of revenue from the sales of Narcan."

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$11.94 /

-0.46 (-3.71%)

OPNT Opiant Pharmaceuticals
$11.94 /

-0.46 (-3.71%)

05/29/19 Northland
Opiant Pharmaceuticals initiated with an Outperform at Northland
OPNT Opiant Pharmaceuticals
$11.94 /

-0.46 (-3.71%)

Earnings
Opiant Pharmaceuticals reports Q1 EPS (40c), consensus (18c) » 16:16
05/12/20
05/12
16:16
05/12/20
16:16
OPNT

Opiant Pharmaceuticals

$11.94 /

-0.46 (-3.71%)

Reports Q1 revenue $4.3M,…

Reports Q1 revenue $4.3M, consensus $4.85M. As of March 31, Opiant had cash and cash equivalents of $32.2M, compared to approximately $31M at December 31, 2019. The current cash balance does not include the full impact of the NIDA grant of approximately $7.4M or the BARDA contract of approximately $4.6M.

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$11.94 /

-0.46 (-3.71%)

OPNT Opiant Pharmaceuticals
$11.94 /

-0.46 (-3.71%)

05/29/19 Northland
Opiant Pharmaceuticals initiated with an Outperform at Northland
OPNT Opiant Pharmaceuticals
$11.94 /

-0.46 (-3.71%)

Hot Stocks
Gritstone Oncology appoints Rahsaan Thompson as general counsel » 08:05
04/06/20
04/06
08:05
04/06/20
08:05
GRTS

Gritstone Oncology

$6.26 /

+0.01 (+0.16%)

, OPNT

Opiant Pharmaceuticals

$8.81 /

-0.055 (-0.62%)

Gritstone Oncology (GRTS)…

Gritstone Oncology (GRTS) announced the appointment of Rahsaan Thompson as its executive vice president and general counsel. Prior to Gritstone, Mr. Thompson was the general counsel for Opiant Pharmaceuticals (OPNT), where he was responsible for all legal aspects of corporate strategy, intellectual property, transactions, compliance and regulatory matters.

ShowHide Related Items >><<
GRTS Gritstone Oncology
$6.26 /

+0.01 (+0.16%)

07/26/19
Fly Intel: Top five analyst initiations
07/25/19 Baird
Gritstone Oncology initiated with an Outperform at Baird
OPNT Opiant Pharmaceuticals
$8.81 /

-0.055 (-0.62%)

05/29/19 Northland
Opiant Pharmaceuticals initiated with an Outperform at Northland
Earnings
Opiant Pharmaceuticals reports Q4 EPS 26c versus ($2.49) last year » 16:13
03/04/20
03/04
16:13
03/04/20
16:13
OPNT

Opiant Pharmaceuticals

$12.48 /

+0.465 (+3.87%)

Reports Q4 revenue $7.7M,…

Reports Q4 revenue $7.7M, consensus $7.63M. "We continue to make good progress advancing our pipeline, and are excited about our expected 2020 milestones," stated Roger Crystal, M.D., President and Chief Executive Officer of Opiant. "There is a large commercial opportunity for each of our products under development, including the market for opioid reversal agents, which we expect to reach approximately $1 billion in 2022. While access to naloxone is critical to save lives, a substantial need continues to exist for stronger, longer-acting opioid antagonists due to the rapid increase in fentanyl-related overdoses. A new report from the Centers for Disease Control and Prevention showed that fentanyl-related drug overdose deaths in 2018 increased 10 percent from 2017."

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$12.48 /

+0.465 (+3.87%)

05/29/19 Northland
Opiant Pharmaceuticals initiated with an Outperform at Northland
03/22/19 Cantor Fitzgerald
Opiant pipeline remains free at current share levels, says Cantor Fitzgerald
Hot Stocks
Opiant Pharmaceuticals, NCATS form collaboration for OPNT004 development » 08:02
01/02/20
01/02
08:02
01/02/20
08:02
OPNT

Opiant Pharmaceuticals

$14.24 /

+0.035 (+0.25%)

, SNY

Sanofi

$50.17 /

+ (+0.00%)

Opiant Pharmaceuticals…

Opiant Pharmaceuticals (OPNT) announced that it has signed a Letter of Intent with the National Center for Advancing Translational Sciences to collaborate on the development of OPNT004, a novel cannabinoid receptor antagonist, for the treatment of Acute Cannabinoid Overdose. NCATS is one of 27 divisions and centers of the National Institutes of Health. NCATS will provide development resources around certain pre-clinical activities and studies in order to support Opiant's planned filing of an Investigational New Drug application for OPNT004. This collaboration will be carried out under a Cooperative Research and Development Agreement between Opiant and the NIH. Opiant licensed exclusive global rights for the development and commercialization of drinabant for the emergency treatment of ACO from Sanofi (SNY) in December 2018. The companies subsequently expanded their partnership in July 2019, whereby Sanofi will be responsible for manufacturing OPNT004.

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$14.24 /

+0.035 (+0.25%)

05/29/19 Northland
Opiant Pharmaceuticals initiated with an Outperform at Northland
03/22/19 Cantor Fitzgerald
Opiant pipeline remains free at current share levels, says Cantor Fitzgerald
SNY Sanofi
$50.17 /

+ (+0.00%)

12/19/19 Jefferies
Jefferies downgrades Synthorx to Hold, doesn't see any additional bidders
12/19/19 Stifel
Principia could rally 35%-75% on Sanofi collaboration decision, says Stifel
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 SVB Leerink
Synthorx downgraded to Market Perform at SVB Leerink following Sanofi deal
Hot Stocks
Fly Intel: After Hours Movers » 18:44
11/12/19
11/12
18:44
11/12/19
18:44
CDLX

Cardlytics

$39.85 /

+0.17 (+0.43%)

, TWOU

2U

$22.58 /

+0.77 (+3.53%)

, OPNT

Opiant Pharmaceuticals

$15.95 /

+0.18 (+1.14%)

, DDOG

Datadog

$34.40 /

+0.89 (+2.66%)

, PTE

PolarityTE

$2.89 /

-0.41 (-12.42%)

, ADPT

Adaptive Biotechnologies

$28.35 /

+0.01 (+0.04%)

, ADT

ADT Inc.

$7.70 /

-0.02 (-0.26%)

, BDSI

BioDelivery Sciences

$5.86 /

+0.02 (+0.34%)

, AQMS

Aqua Metals

$1.45 /

-0.065 (-4.29%)

, YY

JOYY

$65.12 /

-0.28 (-0.43%)

, HUYA

Huya

$24.28 /

-1.05 (-4.15%)

, RUN

Sunrun

$14.49 /

+0.08 (+0.56%)

, VRAY

ViewRay

$2.48 /

-0.145 (-5.53%)

, DZSI

Dasan Zhone

$8.34 /

+0.5 (+6.38%)

, HIIQ

Health Insurance Innovations

$23.27 /

-1.71 (-6.85%)

, CBPX

Continental Building

$35.76 /

+3.73 (+11.65%)

, KNSL

Kinsale Capital Group

$88.98 /

+1.78 (+2.04%)

, BOXL

Boxlight

$1.94 /

+0.19 (+10.86%)

, SSTI

ShotSpotter

$20.36 /

+ (+0.00%)

, TVTY

Tivity Health

$18.56 /

+0.145 (+0.79%)

, GEVO

Gevo

$2.57 /

+0.065 (+2.59%)

, CSIQ

Canadian Solar

$17.51 /

+0.65 (+3.86%)

, SDC

SmileDirectClub

$11.02 /

-0.83 (-7.00%)

, SWKS

Skyworks

$101.59 /

+1.22 (+1.22%)

, VREX

Varex Imaging

$32.68 /

+0.1 (+0.31%)

, TLRY

Tilray

$21.57 /

-0.4 (-1.82%)

, NXTC

NextCure

$37.41 /

-1.45 (-3.73%)

, HALO

Halozyme

$16.77 /

+0.18 (+1.09%)

, CYBR

CyberArk

$115.30 /

+1.45 (+1.27%)

, I

Intelsat

$20.39 /

-2.845 (-12.24%)

UP AFTER EARNINGS: …

UP AFTER EARNINGS: Cardlytics (CDLX) up 24.2%... 2U (TWOU) up 14.5%... Opiant Pharma (OPNT) up 13.7%... DataDog (DDOG) up 13.3%... Polarity (PTE) up 8.3%... Adaptive Biotech (ADPT) up 5.8%... ADT Inc (ADT) up 5.8%... BioDelivery Sciences (BDSI) up 5.0%... Aqua Metals (AQMS) up 4.8%... YY (YY) up 4.0%... Huya (HUYA) up 3.9%... SunRun (RUN) up 2.9%... ViewRay (VRAY) up 2.8%... DASAN Zhone Solutions (DZSI) up 2.4%... Health Insurance Innovations (HIIQ) up 2.1%... Continental Building (CBPX) up 1.5%. ALSO HIGHER: Kinsale Capital (KNSL) up 8.2% after entering S&P SmallCap 600 index. DOWN AFTER EARNINGS: Boxlight (BOXL) down 15.3%... ShotSpotter (SSTI) down 12.1%... Tivity Health (TVTY) down 11.9%... Gevo (GEVO) down 9.8%... Canadian Solar (CSIQ) down 9.5%... SmileDirectClub (SDC) down 7.3%... Skyworks (SWKS) down 5.2%... Varex Imaging (VREX) down 3.6%... Tilray (TLRY) down 2.2%. ALSO LOWER: NextCure (NXTC) down 8.9% after equity offering... Halozyme (HALO) down 4.9% after convertible debt offering... CyberArk Software (CYBR) down 3.0% after convertible debt offering... Intelsat (I) down 2.9% after being downgraded to Neutral at JPMorgan. Movers as of 18:15ET.

ShowHide Related Items >><<
CDLX Cardlytics
$39.85 /

+0.17 (+0.43%)

08/09/19
Fly Intel: Top five analyst downgrades
08/09/19 Truist
Cardlytics price target raised to $35 from $25 at SunTrust
08/09/19
Cardlytics downgraded to Sector Weight from Overweight at KeyBanc
08/08/19 KeyBanc
Cardlytics downgraded to Sector Weight from Overweight at KeyBanc
TWOU 2U
$22.58 /

+0.77 (+3.53%)

10/17/19 DA Davidson
2U price target lowered to $17 from $27 at DA Davidson
08/13/19 William Blair
William Blair starts Chegg, K12 with Outperform ratings
08/12/19 William Blair
2U initiated with a Market Perform at William Blair
08/08/19 Citi
2U reinstated with a Buy at Citi
OPNT Opiant Pharmaceuticals
$15.95 /

+0.18 (+1.14%)

05/29/19 Northland
Opiant Pharmaceuticals initiated with an Outperform at Northland
03/22/19 Cantor Fitzgerald
Opiant pipeline remains free at current share levels, says Cantor Fitzgerald
DDOG Datadog
$34.40 /

+0.89 (+2.66%)

11/06/19 Credit Suisse
Datadog initiated with a Neutral at Credit Suisse on valuation
11/06/19 Credit Suisse
Datadog initiated with a Neutral at Credit Suisse
10/24/19 Morgan Stanley
Morgan Stanley says Datadog has best setup in infrastructure software
10/14/19
Fly Intel: Top five analyst initiations
PTE PolarityTE
$2.89 /

-0.41 (-12.42%)

11/11/19 Cantor Fitzgerald
Cantor assumes PolarityTE at Overweight, cuts target to $13 from $50
09/23/19 Cantor Fitzgerald
Cantor 'enthusiastic' about changes taking place at PolarityTE
08/20/19 Cantor Fitzgerald
PolarityTE's patent approval increases probability of patent protection, says Cantor Fitzgerald
08/09/19 Oppenheimer
PolarityTE price target lowered to $14 from $24 at Oppenheimer
ADPT Adaptive Biotechnologies
$28.35 /

+0.01 (+0.04%)

07/23/19
Fly Intel: Top five analyst initiations
07/23/19 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
07/22/19 William Blair
Adaptive Biotechnologies initiated with an Outperform at William Blair
07/22/19 Guggenheim
Adaptive Biotechnologies initiated with a Buy at Guggenheim
ADT ADT Inc.
$7.70 /

-0.02 (-0.26%)

05/13/19
Fly Intel: Top five analyst downgrades
05/13/19 Morgan Stanley
ADT Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
03/15/19 Imperial Capital
ADT Inc. price target lowered to $12 from $15 at Imperial Capital
03/12/19 Citi
ADT Inc. downgraded to Neutral from Buy at Citi
BDSI BioDelivery Sciences
$5.86 /

+0.02 (+0.34%)

09/17/19 William Blair
Purdue bankruptcy positive for Collegium and BioDelivery, says William Blair
04/16/19 Cantor Fitzgerald
BioDelivery acquisitoin of Symproic a positive, says Cantor Fitzgerald
03/19/19 Truist
BioDelivery Sciences initiated with a Buy at SunTrust
01/31/19
Fly Intel: Top five analyst initiations
AQMS Aqua Metals
$1.45 /

-0.065 (-4.29%)

05/15/19 Oppenheimer
Aqua Metals price target lowered to $9 from $14 at Oppenheimer
YY JOYY
$65.12 /

-0.28 (-0.43%)

09/20/19 UBS
YY upgraded to Buy from Neutral at UBS
09/20/19 UBS
YY upgraded to Buy from Neutral at UBS
08/05/19 Jefferies
YY initiated with a Buy at Jefferies
07/15/19 Nomura Instinet
YY target raised to $79 ahead of Q2 results at Nomura Instinet
HUYA Huya
$24.28 /

-1.05 (-4.15%)

09/16/19 HSBC
Huya initiated with a Buy at HSBC
08/14/19 CLSA
Huya upgraded to Buy from Outperform at CLSA
08/14/19 Daiwa
Huya upgraded to Buy from Outperform at Daiwa
08/05/19 Jefferies
Huya initiated with a Buy at Jefferies
RUN Sunrun
$14.49 /

+0.08 (+0.56%)

08/20/19
Fly Intel: Top five analyst initiations
08/20/19
KeyBanc bullish on Sunnova Energy, initiates with an Overweight
08/20/19
KeyBanc bullish on Sunrun, initiates with an Overweight
08/19/19 KeyBanc
Sunrun initiated with an Overweight at KeyBanc
VRAY ViewRay
$2.48 /

-0.145 (-5.53%)

10/21/19 Oppenheimer
Oppenheimer starts ViewRay with Outperform rating, $7 price target
10/21/19 Oppenheimer
ViewRay initiated with an Outperform at Oppenheimer
10/15/19 Piper Sandler
ViewRay preannounced better than expected Q3, says Piper Jaffray
09/16/19 Piper Sandler
ViewRay recent orders 'incremental positives,' says Piper Jaffray
DZSI Dasan Zhone
$8.34 /

+0.5 (+6.38%)

10/08/19 Northland
Dasan Zhone price target lowered to $15.50 from $20.00 at Northland
07/09/19 B. Riley FBR
B. Riley FBR says China supply chain internalization issue for optical industry
05/20/19 B. Riley FBR
Dasan Zhone initiated with a Buy at B. Riley FBR
HIIQ Health Insurance Innovations
$23.27 /

-1.71 (-6.85%)

09/25/19 B. Riley FBR
Health Insurance should be bought on yesterday's selloff, says B. Riley FBR
09/20/19
Health Insurance Innovations management to meet with B. Riley FBR
08/16/19 Piper Sandler
Teladoc short report selloff brings buying opportunity, says Piper Jaffray
08/13/19 Cantor Fitzgerald
Health Insurance cash flow not major concern, says Cantor Fitzgerald
CBPX Continental Building
$35.76 /

+3.73 (+11.65%)

10/09/19 Exane BNP Paribas
Continental Building initiated with an Outperform rating at Exane BNP Paribas
06/14/19 Longbow
Eagle Materials, Continental Building estimates lowered after survey at Longbow
04/17/19
Continental Building cut to Sector Perform at RBC Capital on weaker pricing
04/17/19 RBC Capital
Continental Building downgraded to Sector Perform at RBC Capital
KNSL Kinsale Capital Group
$88.98 /

+1.78 (+2.04%)

09/26/19 UBS
Kinsale Capital Group price target raised to $112 from $98 at UBS
09/06/19 JMP Securities
Kinsale Capital Group initiated with a Market Perform at JMP Securities
07/01/19 Truist
Kinsale Capital Group price target raised to $100 from $85 at SunTrust
02/25/19 Truist
Kinsale Capital Group price target raised to $75 from $66 at SunTrust
BOXL Boxlight
$1.94 /

+0.19 (+10.86%)

10/22/19 National Securities
Boxlight initiated with a Buy at National Securities
04/10/19 Maxim
Boxlight initiated with a Buy at Maxim
SSTI ShotSpotter
$20.36 /

+ (+0.00%)

10/18/19 Imperial Capital
ShotSpotter price target lowered to $38 from $48 at Imperial Capital
09/27/19 B. Riley FBR
ShotSpotter removed from Alpha Generator list at B. Riley FBR
08/07/19 Lake Street
ShotSpotter price target lowered to $40 from $50 at Lake Street
08/06/19 William Blair
ShotSpotter downgraded to Market Perform from Outperform at William Blair
TVTY Tivity Health
$18.56 /

+0.145 (+0.79%)

08/26/19 Cantor Fitzgerald
Tivity Health shares remain inexpensive, says Cantor Fitzgerald
08/08/19 Barrington
Tivity Health shares offer over 100% upside potential, says Barrington
08/08/19 Piper Sandler
Tivity Health price target lowered to $25 from $33 at Piper Jaffray
05/09/19 Oppenheimer
Tivity Health price target raised to $36 from $31 at Oppenheimer
GEVO Gevo
$2.57 /

+0.065 (+2.59%)

CSIQ Canadian Solar
$17.51 /

+0.65 (+3.86%)

10/07/19 Goldman Sachs
Goldman says U.S. solar makers should benefit from end of bifacial exemption
08/16/19 Roth Capital
Canadian Solar price target raised to $32 from $27 at Roth Capital
04/11/19
Fly Intel: Top five analyst initiations
04/11/19 JPMorgan
Canadian Solar assumed with a Neutral at JPMorgan
SDC SmileDirectClub
$11.02 /

-0.83 (-7.00%)

10/28/19 JPMorgan
JPMorgan calls SmileDirectClub 'one of the best buying opportunities' it covers
10/23/19 Guggenheim
Guggenheim says SmileDirect California situation more unique than first thought
10/17/19 Credit Suisse
SmileDirectClub reaction to CA Assembly Bill 1519 overdone, says Credit Suisse
10/15/19 Guggenheim
SmileDirectClub should consider pre-announcing Q3 results, says Guggenheim
SWKS Skyworks
$101.59 /

+1.22 (+1.22%)

11/12/19 BMO Capital
Skyworks price target raised to $120 from $100 at BMO Capital
11/11/19 Cowen
Skyworks should see slight upside to Q3 estimates, says Cowen
11/01/19 B. Riley FBR
Skyworks price target raised to $105 from $95 at B. Riley FBR
10/10/19
Fly Intel: Top five analyst upgrades
VREX Varex Imaging
$32.68 /

+0.1 (+0.31%)

10/21/19 Oppenheimer
Oppenheimer starts Varex Imaging at Outperform with $40 price target
10/21/19 Oppenheimer
Varex Imaging initiated with an Outperform at Oppenheimer
09/09/19
Varex Imaging management to meet with Sidoti
06/11/19
Varex Imaging upgraded to Market Outperform from Perform at CJS Securities
TLRY Tilray
$21.57 /

-0.4 (-1.82%)

11/05/19 BofA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
11/05/19 Cantor Fitzgerald
Tilray initiated with a Neutral at Cantor Fitzgerald
11/04/19 Cantor Fitzgerald
Tilray initiated with a Neutral at Cantor Fitzgerald
10/25/19 Jefferies
Tilray clinical trial update yesterday a positive, says Jefferies
NXTC NextCure
$37.41 /

-1.45 (-3.73%)

11/11/19 Piper Sandler
NextCure price target raised to $95 from $54 at Piper Jaffray
09/04/19 Piper Sandler
NextCure price target raised to $54 from $26 at Piper Jaffray
07/10/19 Piper Sandler
NextCure should be owned ahead of NC318 data, says Piper Jaffray
07/09/19 BofA
NextCure initiated with a Buy at BofA/Merrill
HALO Halozyme
$16.77 /

+0.18 (+1.09%)

11/05/19 Barclays
Halozyme upgraded to Equal Weight after HALO-301 failure at Barclays
11/05/19 Barclays
Halozyme upgraded to Equal Weight from Underweight at Barclays
09/11/19 Cantor Fitzgerald
Halozyme offers 'low-risk/high-reward' event in Q4, says Cantor Fitzgerald
07/01/19 Cantor Fitzgerald
Halozyme price target raised to $27 from $24 at Cantor Fitzgerald
CYBR CyberArk
$115.30 /

+1.45 (+1.27%)

11/08/19 Piper Sandler
CyberArk assumed with a Neutral at Piper Jaffray
08/21/19 Cowen
CyberArk initiated with an Outperform at Cowen
08/07/19 JPMorgan
CyberArk price target raised to $160 from $125 at JPMorgan
08/07/19
CyberArk selloff on CRO exit 'overreaction' a buying opportunity, says Dougherty
I Intelsat
$20.39 /

-2.845 (-12.24%)

11/12/19 JPMorgan
Intelsat downgraded to Neutral on 'more complicated' C-Band outlook at JPMorgan
11/12/19 JPMorgan
Intelsat downgraded to Neutral from Overweight at JPMorgan
09/19/19 JPMorgan
Intelsat price target raised to $32 from $27 at JPMorgan
04/17/19 Goldman Sachs
Sprint, T-Mobile headlines positive for Dish, Intelsat, says Goldman Sachs
  • 15
    Nov
Earnings
Opiant Pharmaceuticals reports Q3 EPS $1.97, consensus (9c) » 16:29
11/12/19
11/12
16:29
11/12/19
16:29
OPNT

Opiant Pharmaceuticals

$15.95 /

+0.18 (+1.14%)

Reports Q3 revenue…

Reports Q3 revenue $20.6M, consensus $5.52M. David O'Toole, CFO, says, "I am extremely pleased to report that, based on net sales of NARCAN Nasal Spray exceeding $200 million through the third quarter of 2019, we have earned a one-time $13.5 million milestone. After certain required deductions, the net milestone payment of $10.8 million will further fortify our already strong balance sheet, and we now expect a cash balance of $28 million to $30 million at the end of 2019, versus our prior projection of $17 million to $20 million."

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$15.95 /

+0.18 (+1.14%)

05/29/19 Northland
Opiant Pharmaceuticals initiated with an Outperform at Northland
03/22/19 Cantor Fitzgerald
Opiant pipeline remains free at current share levels, says Cantor Fitzgerald
Conference/Events
Dawson James to hold a conference » 04:55
10/29/19
10/29
04:55
10/29/19
04:55
AIM

AIM ImmunoTech

$0.52 /

-0.0304 (-5.53%)

, ARTL

Artelo Biosciences

$2.42 /

+0.05 (+2.11%)

, ATOS

Atossa Therapeutics

$1.74 /

+0.015 (+0.87%)

, AZRX

AzurRx BioPharma

$0.67 /

+0.0042 (+0.63%)

, BCDA

BioCardia

$4.41 /

+ (+0.00%)

, BCLI

BrainStorm

$3.70 /

+0.02 (+0.54%)

, BYSI

BeyondSpring

$12.42 /

+0.03 (+0.24%)

, CANF

Can-Fite BioPharma

$2.13 /

+0.035 (+1.67%)

, CLBS

Caladrius

$2.17 /

+0.01 (+0.46%)

, CLSN

Celsion

$1.73 /

+0.01 (+0.58%)

, CTXR

Citius Pharmaceuticals

$0.55 /

-0.0302 (-5.21%)

, CVM

CEL-SCI

$7.17 /

+0.34 (+4.98%)

, DMPI

DelMar Pharmaceuticals

$0.57 /

+0.0039 (+0.69%)

, FBIO

Fortress Biotech

$1.33 /

-0.04 (-2.92%)

, HOTH

Hoth Therapeutics

$3.66 /

-0.55 (-13.06%)

, IDXG

Interpace Biosciences

$0.81 /

-0.0137 (-1.67%)

, KOOL

Ticker changed to THMO

$4.33 /

-0.3 (-6.48%)

, LCTX

Lineage Cell Therapeutics

$0.87 /

+0.0171 (+2.01%)

, MESO

Mesoblast

$5.92 /

-0.22 (-3.58%)

, OPNT

Opiant Pharmaceuticals

$15.55 /

-0.15 (-0.96%)

, ORGS

Orgenesis

$3.50 /

-0.04 (-1.13%)

, SPHS

Sophiris Bio

$0.57 /

-0.0004 (-0.07%)

, TNXP

Tonix Pharmaceuticals

$0.34 /

-0.0589 (-14.86%)

, URG

UR-Energy

$0.59 /

+0.007 (+1.20%)

, VNRX

VolitionRx

$5.83 /

-0.145 (-2.43%)

, ZYNE

Zynerba

$8.15 /

+0.04 (+0.49%)

2019 Annual Small Cap…

2019 Annual Small Cap Growth Stock Conference will be held in Jupiter, FL on October 28-29.

ShowHide Related Items >><<
AIM AIM ImmunoTech
$0.52 /

-0.0304 (-5.53%)

10/10/19 Maxim
AIM ImmunoTech has removed financing overhang, says Maxim
10/10/19 Maxim
AIM ImmunoTech upgraded to Buy from Hold at Maxim
ARTL Artelo Biosciences
$2.42 /

+0.05 (+2.11%)

07/09/19 Maxim
Artelo Biosciences initiated with a Buy at Maxim
07/09/19 Maxim
Artelo Biosciences initiated with a Buy at Maxim
ATOS Atossa Therapeutics
$1.74 /

+0.015 (+0.87%)

06/27/19 Maxim
Maxim downgrades Atossa Genetics to Hold on high endoxifen discontinuations
06/27/19 Maxim
Atossa Genetics downgraded to Hold from Buy at Maxim
AZRX AzurRx BioPharma
$0.67 /

+0.0042 (+0.63%)

06/11/19 National Securities
AzurRx BioPharma initiated with a Buy at National Securities
02/14/19 Maxim
AzurRx BioPharma initiated with a Buy at Maxim
01/25/19
Fly Intel: Top five analyst initiations
01/25/19 Roth Capital
AzurRx BioPharma initiated with a Buy at Roth Capital
BCDA BioCardia
$4.41 /

+ (+0.00%)

10/10/19
Fly Intel: Top five analyst initiations
10/10/19 Maxim
BioCardia initiated with a Buy, $9 price target at Maxim
10/10/19 Maxim
BioCardia initiated with a Buy rating at Maxim
BCLI BrainStorm
$3.70 /

+0.02 (+0.54%)

10/29/18 H.C. Wainwright
BrainStorm's 'distressed valuation' presents opportunity, says H.C. Wainwright
BYSI BeyondSpring
$12.42 /

+0.03 (+0.24%)

07/10/19 H.C. Wainwright
BeyondSpring price target lowered to $41 from $60 at H.C. Wainwright
04/30/19 Maxim
BeyondSpring downgraded to Hold from Buy at Maxim
04/30/19 H.C. Wainwright
BeyondSpring 'investment thesis remains strong,' says H.C. Wainwright
12/06/18 H.C. Wainwright
BeyondSpring delivers important milestone, says H.C. Wainwright
CANF Can-Fite BioPharma
$2.13 /

+0.035 (+1.67%)

03/27/19 H.C. Wainwright
Can-Fite selloff yesterday on trial miss unwarranted, says H.C. Wainwright
10/31/18 H.C. Wainwright
H.C. Wainwright 'cautiously optimistic' about Can-Fite after trial results delay
CLBS Caladrius
$2.17 /

+0.01 (+0.46%)

01/24/19 H.C. Wainwright
Caladrius an 'intriguing opportunity' near cash levels, says H.C. Wainwright
11/20/18 H.C. Wainwright
Caladrius assumed with a Buy at H.C. Wainwright
CLSN Celsion
$1.73 /

+0.01 (+0.58%)

CTXR Citius Pharmaceuticals
$0.55 /

-0.0302 (-5.21%)

02/07/19 H.C. Wainwright
Citius Pharmaceuticals assumed with a Buy at H.C. Wainwright
CVM CEL-SCI
$7.17 /

+0.34 (+4.98%)

DMPI DelMar Pharmaceuticals
$0.57 /

+0.0039 (+0.69%)

09/06/19 Maxim
DelMar Pharmaceuticals initiated with a Buy at Maxim
FBIO Fortress Biotech
$1.33 /

-0.04 (-2.92%)

08/26/19 Dawson James
Fortress Biotech initiated with a Buy at Dawson James
07/01/19
Fly Intel: Top five analyst initiations
07/01/19 Roth Capital
Fortress Biotech initiated with a Buy at Roth Capital
04/18/19 H.C. Wainwright
H.C. Wainwright says Fortress business model validated by Mustang data
HOTH Hoth Therapeutics
$3.66 /

-0.55 (-13.06%)

10/15/19 Benchmark
Hoth Therapeutics initiated with a Speculative Buy at Benchmark
05/20/19 Laidlaw
Hoth Therapeutics initiated with a Buy at Laidlaw
IDXG Interpace Biosciences
$0.81 /

-0.0137 (-1.67%)

09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer
KOOL Ticker changed to THMO
$4.33 /

-0.3 (-6.48%)

10/03/19 H.C. Wainwright
Cesca Therapeutics price target raised to $7.50 from $6.50 at H.C. Wainwright
08/14/19 H.C. Wainwright
Cesca Therapeutics price target raised to $6.50 from $1 at H.C. Wainwright
LCTX Lineage Cell Therapeutics
$0.87 /

+0.0171 (+2.01%)

MESO Mesoblast
$5.92 /

-0.22 (-3.58%)

10/22/19 Cantor Fitzgerald
Mesoblast assumed with an Overweight at Cantor Fitzgerald
09/10/19 Cantor Fitzgerald
Mesoblast partnership deal with Grunenthal a positive, says Cantor Fitzgerald
01/31/19 H.C. Wainwright
Mesoblast assumed with a Buy at H.C. Wainwright
OPNT Opiant Pharmaceuticals
$15.55 /

-0.15 (-0.96%)

05/29/19 Northland
Opiant Pharmaceuticals initiated with an Outperform at Northland
03/22/19 Cantor Fitzgerald
Opiant pipeline remains free at current share levels, says Cantor Fitzgerald
ORGS Orgenesis
$3.50 /

-0.04 (-1.13%)

09/26/19 Benchmark
Orgenesis initiated with a Speculative Buy at Benchmark
12/20/18 Dawson James
Orgenesis initiated with a Buy at Dawson James
SPHS Sophiris Bio
$0.57 /

-0.0004 (-0.07%)

10/21/19 H.C. Wainwright
Sophiris trial greenlight from FDA removes a key overhang, says H.C. Wainwright
03/20/19 JonesTrading
Sophiris Bio downgraded to Hold from Buy at JonesTrading
03/14/19 H.C. Wainwright
Sophiris Bio price target lowered to $3.50 from $10 at H.C. Wainwright
03/13/19 Piper Sandler
Sophiris Bio price target lowered to $5 from $7 at Piper Jaffray
TNXP Tonix Pharmaceuticals
$0.34 /

-0.0589 (-14.86%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
04/18/19
Tonix Pharmaceuticals upgraded to Buy at Roth Capital
04/18/19 Roth Capital
Tonix Pharmaceuticals upgraded to Buy from Neutral at Roth Capital
URG UR-Energy
$0.59 /

+0.007 (+1.20%)

VNRX VolitionRx
$5.83 /

-0.145 (-2.43%)

ZYNE Zynerba
$8.15 /

+0.04 (+0.49%)

10/21/19 Needham
Zynerba initiated with a Buy at Needham
10/10/19 Stifel
Hexo miss further damages cannabis industry credibility, says Stifel
09/19/19 H.C. Wainwright
Zynerba selloff on open-label data for Zygel 'unwarranted,' says H.C. Wainwright
09/19/19 Canaccord
Zynerba data confusion creates buying opportunity, says Canaccord

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.